The role of red blood cells and hemoglobin-nitric oxide interactions on blood flow

American Journal of Respiratory Cell and Molecular Biology

Volumn 38, Issue 2, 2008, Pages 125-126

  Gladwin, Mark T ^a   Patel, Rakesh P ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; METHEMOGLOBIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYHEMOGLOBIN;

BLOOD FLOWMETRY; CONTROLLED STUDY; EDITORIAL; ERYTHROCYTE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; MEAN ARTERIAL PRESSURE; PATHOGENESIS; SHEAR STRESS; VASCULAR RESISTANCE; VASODILATATION; VISCOSITY;

BLOOD CIRCULATION; ERYTHROCYTES; HEMOGLOBINS; HUMANS; NITRIC OXIDE;

EID: 38549139987     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2007-0006ED     Document Type: Editorial

References (22)

1. Salazar Vazquez BY, Cabrales P, Tsai AG, Johnson PC, Intaglietta M. Lowering of blood pressure by increasing hematocrit with non-nitric oxide-scavenging red blood cells. Am J Respir Cell Mol Biol 2008;38:135-142.
2. Minneci PC, Deans KJ, Zhi H, Yuen PS, Star RA, Banks SM, Schechter AN, Natanson C, Gladwin MT, Solomon SB. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest 2005;115:3409-3417.
3. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO III. Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J Clin Invest 1995;95:1747-1755.
4. Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 2003;348:1483-1485.
5. Ellsworth ML, Forrester T, Ellis CG, Dietrich HH. The erythrocyte as a regulator of vascular tone. Am J Physiol 1995;269:H2155-H2161.
6. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003;9:1498-1505.
7. Crawford JH, Isbell TS, Huang Z, Shiva S, Chacko BK, Schechter AN, Darley-Usmar VM, Kerby JD, Lang JD Jr, Kraus D, et al. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 2006;107:566-574.
8. Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol 2006;26:697-705.
9. Olson JS, Foley EW, Rogge C, Tsai AL, Doyle MP, Lemon DD. No scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med 2004;36:685-697.
10. Coin JT, Olson JS. The rate of oxygen uptake by human red blood cells. J Biol Chem 1979;254:1178-1190.
11. Liu X, Miller MJ, Joshi MS, Sadowska-Krowicka H, Clark DA, Lancaster JR Jr. Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem 1998;273:18709-18713.
12. Butler AR, Megson IL, Wright PG. Diffusion of nitric oxide and scavenging by blood in the vasculature. Biochim Biophys Acta 1998;1425:168-176.
13. Huang KT, Han TH, Hyduke DR, Vaughn MW, Van Herle H, Hein TW, Zhang C, Kuo L, Liao JC. Modulation of nitric oxide bioavailability by erythrocytes. Proc Natl Acad Sci USA 2001;98:11771-11776.
14. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005;293:1653-1662.
15. Sloan EP, Koenigsberg M, Brunett PH, Bynoe RP, Morris JA, Tinkoff G, Dalsey WC, Ochsner MG. Post hoc mortality analysis of the efficacy trial of diaspirin cross- linked hemoglobin in the treatment of severe traumatic hemorrhagic shock. J Trauma 2002;52:887-895.
16. Reiter CD, Gladwin MT. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol 2003;10:99-107.
17. Lappin TR, Maxwell AP, Johnston PG. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia. Oncologist 2007;12:362-365.
18. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-388.
19. Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC. Haemoglobin targets: we were wrong, time to move on. Lancet 2007;369:346-350.
20. Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C, Wagner K, Labugger R, Kelm M, Noll G, Rulicke T, et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 2000;97:11609-11613.
21. Azarov I, Huang KT, Basu S, Gladwin MT, Hogg N, Kim-Shapiro DB. Nitric oxide scavenging by red blood cells as a function of hematocrit and oxygenation. J Biol Chem 2005;280:39024-39032.
22. Jeffers A, Gladwin MT, Kim-Shapiro DB. Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias. Free Radic Biol Med 2006;41:1557-1565.